RE:RE:RE:RE:Big pharmas in the ultra-competitive bladder cancer market
CancerSlayer wrote: Thanks guys for your input...Dr. Kamat did seem hopeful about our ACT being a potential stand-alone option or being used in combination with other immunotherapies. And I agree, using TLD-1433 as a combo agent should perform at least as well as the other combo therapies currently under investigation. The fact that our ACT could potentially be done using only a "single" treatment for a recurrence or for a partial/non-responder (vs multiple maintenance/reinduction treatments that would likely be required by other therapies) should bode well for our ACT's future adoption. All imo.
I will take back everything I said in my previous post....most everything ; ). Good luck...
Thought I would elaborate....if the current combo drug trials are successful (though certainly not guaranteed to be superior to our ACT used as a combo agent), there would certainly be additional competition for this indication. To convince docs to use our ACT + "X" drug combo treatment (a sort of off-label combo vs single-drug use), our ACT will have to be able to successfully treat the other combo treatment cases that are resistant, or show at least similar efficacy to any other combo therapies with the big advantage of not needing excessive treatment visits.
If TLT can set a precedent as being a superior single-agent treatment option in BCG-unresponsive NMIBC & perhaps as well in one additional indication (I.e. NSCLC), I think our ACT in time can become an accepted & more widely-used treatment (as a single or combo agent) for other cancers, even though the FDA has not approved our ACT for those uses. Dcoumented success stories in clinical practice could translate into further expedited clinical trials, resulting in more rapid adoption & more rapid expansion of our indications.
In the end, docs, hospitals & academic centers will have to gravitate towards what works best, what is in the patient's best interests & what governments/insurance companies/patients demand, whether it be on-label or off-label....many drugs currently used in children have been based on FDA approved studies in adults...subsequently dose adjusted. JMO.